BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure
Officers and representatives of the Company will present to various investors and stockholders beginning May 23, 2018 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference.
The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
BIOSPECIFICS TECHNOLOGIES CORP ExhibitEX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 BioSpecifics Technology Corp….To view the full exhibit click here
About BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC)
BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. Its injectable collagenases are marketed for indications, such as Dupuytren’s contracture and Peyronie’s disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren’s contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.